Rituxan (rituximab)

Although the R-CHOP regimen has significantly improved the prognosis for most patients, a subset continues to experience poor therapeutic outcomes...The key gene TRPV2, associated with favorable prognosis, was found to promote M1-like polarization in monocytes/macrophages and enhance antigen presentation in B cells. This study establishes the NR risk score as a novel prognostic tool for DLBCL and underscores neuro-immune interactions as potential therapeutic targets.

P1, N=17, Active, not recruiting, Byondis B.V. | Recruiting --> Active, not recruiting | N=100 --> 17 | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

P3, N=80, Enrolling by invitation, Second Affiliated Hospital of Nanchang University

Kaplan-Meier analysis of R-CHOP-treated patients with DLBCL-NOS revealed that those with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.

Unexplained splenomegaly warrants consideration of primary splenic lymphoma in the differential diagnosis, even without lymphadenopathy or classic B symptoms, particularly when detected during abdominal imaging for hepatosplenic evaluation.Histopathologic and molecular confirmation is essential, as indolent subtypes (e.g. SMZL) and aggressive subtypes (e.g. DLBCL) may present identically but require fundamentally different treatment approaches.PET/CT-guided diagnostic strategy optimises outcomes by enabling accurate staging, identifying the most metabolically active site for biopsy, and informing the need for splenectomy versus direct systemic therapy.

P3, N=122, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting

P2, N=84, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Dec 2026 | Trial primary completion date: Sep 2027 --> Dec 2026

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026

P3, N=92, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

The patient was managed sequentially with anti-tuberculous therapy (ATT) followed by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, achieving complete remission at six months with 12-month disease-free follow-up. In patients undergoing lymph node biopsy for suspected tuberculosis, it is crucial to thoroughly assess for an underlying lymphoma. Detecting a malignancy in a cervical tuberculous lymph node significantly alters the therapeutic approach and requires coordinated management with medical oncology specialists.

P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027

P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting